Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06215040Recruiting

The Treatment Effect for Asymptomatic Common Bile Duct Stone

Role: collaborator

NCT03222258Completed

Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients

Role: collaborator

NCT03181854Not ApplicableCompleted

Randomized Controlled Trial of Integrated Early Palliative Care

Role: collaborator

NCT03252678Not ApplicableCompleted

Efficacy of Self-education Program for Advanced Care Planning(RCT)

Role: collaborator

NCT01672476Phase 3Completed

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Role: collaborator

All 5 trials loaded